Pancreatic cancer breakthrough prompts shift toward early-detection era
A new pancreatic cancer drug, daraxonrasib, has shown the ability to double median survival in advanced cases versus chemotherapy, fueling optimism about treating the disease earlier. At UC San Diego’s Moores Cancer Center, researchers note that early intervention could maximize benefits as part of PRECEDE, a global program screening at‑risk individuals with regular blood tests and imaging across 65 centers, with about 12,000 of 20,000 enrolled and roughly 75% of detected cases currently found at stage I. AI in imaging is anticipated to boost early detection, while the FDA has granted expanded access to the drug for patients not eligible for trials. Experts envision “interception studies” that could use RAS inhibitors earlier to prevent spread, potentially combining resection with targeted therapy for even better outcomes.
